 LEXINGTON, Mass., April 27, 2021 PRNewswire -- LogicBio Therapeutics, Inc. Nasdaq:LOGC, a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced an update on screening and enrollment activities for the SUNRISE Phase III clinical trial of LB-001, the companys investigational treatment for methylmalonic acidemia MMA based on LogicBios proprietary gene insertion platform, GeneRideTM. 